 IRVINE, Calif., Sept. 01, 2021 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis ALS, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the HC Wainwright 23rd Annual Global Investment Conference. The companys presentation will be available on-demand beginning on Monday, September 13 at 7:00am EST. 